Science
Chronic Kidney Disease
Explore
Chronic Kidney Disease (CKD) is a progressive condition leading to eventual loss of kidney function. Epidemiology studies estimate that more than 10% of the general population, or greater than 800 million people worldwide, have CKD. It is one of the leading causes of mortality and carries significant economic burden on individuals and the healthcare system.
Patients with diabetes and heart failure are especially at risk of developing kidney disease due to the increased demand placed on the kidney. Selective SGLT2 inhibitors have demonstrated that they are effective agents in reducing the progression of kidney disease. The underlying mechanisms are multi-faceted and still being uncovered, with new insights being developed every day.New evidence suggests that dual SGLT1 and SGLT2 inhibitors could have superior clinical efficacy over selective SGLT2 inhibitors.
YG1699, a dual systemic SGLT1 and SGLT2 inhibitor, inhibits SGLT2 in the early proximal tubule as well as SGLT1 expressed in the late proximal tubule of the nephron. In the small intestinal tract, YG1699 inhibits SGLT1-mediated glucose absorption and induces secretion of GLP-1/PYY. The associated benefits could lead to such benefits as better glycemic control, and improved glomerular filtration rate (GFR) and kidney oxygenation versus selective SGLT2 inhibitors. Together, such attributes could further delay the onset of kidney and heart failure by preserving kidney function.
